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Abstract
There are two types of pyloric gland-like metaplasia in the corpus of stomach: pyloric and pseudopyloric metaplasias. They show
the same morphology as the original pyloric glands in H&E staining. Pseudopyloric metaplasia is positive for pepsinogen (PG) I
immunohistochemically, whereas pyloric metaplasia is negative. Recently, spasmolytic polypeptide-expressing metaplasia
(SPEM) is proposed for pyloric gland-like metaplasia mainly in animal experiments. SPEM expresses trefoil factor family 2
(TFF2) and is often considered synonymous with pseudopyloric metaplasia. We reviewed consecutive 22 Japanese patients with
autoimmune gastritis (AIG) to investigate TFF2 expression in pyloric and pseudopyloric metaplasias by counting all pyloric
gland-like glands in biopsy specimens taken from greater curvature of the middle corpus according to the Updated Sydney
System. Pyloric metaplasia was seen in all the 22 cases, and pseudopyloric metaplasia was found in 15 cases. Of 1567 pyloric
gland-like glands in all the cases, 1381 (88.1%) glands were pyloric metaplasia glands, and the remaining 186 (11.9%) glands
were pseudopyloric metaplasia glands. TFF2 expression was observed in pyloric or pseudopyloric metaplasia glands in 20 cases.
TFF2 expression was recognized in 409 of 1381 (26.9%) pyloric metaplasia glands and 27 of 186 (14.5%) pseudopyloric
metaplasia glands (P<0.01, chi-square test). In conclusion, SPEM was not always the same as pseudopyloric metaplasia in
human AIG, and the majority of metaplasia in AIG was not pseudopyloric but pyloric metaplasia.
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Introduction
Metaplasia is a phenomenon in which one adult cell type is
replaced by another adult cell type [1]. In stomach, various
types of metaplasias have been described. Intestinal meta-
plasia is one of the representative metaplasias in the stom-
ach which consists of large or small intestinal mucosa lo-
cated in the places where gastric mucosa should have
existed [1]. Pyloric/pseudopyloric metaplasia is another
representative metaplasia which consists of pyloric gland
mucosa located in the places where fundic gland mucosa
should have existed [2–4]. Pancreatic acinar cell metaplasia
is a cluster composed of pancreatic acinar cells in stomach
[5–7].
Pyloric metaplasia is stained same as original pyloric gland
mucosa with hematoxylin and eosin (H&E) and with immu-
nohistochemical staining for MUC6. Pseudopyloric
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metaplasia is also stained the same as original pyloric gland
mucosa with H&E but positive for pepsinogen (PG) I
immunohistochemically, whereas pyloric metaplasia is nega-
tive [3]. Unfortunately, in many papers, pyloric and
pseudopyloric metaplasias have not been described separately
and are often treated as collectively “pyloric or pseudopyloric
metaplasia” [4].
Recently, trefoil factor family 2 (TFF2) expression in the
stomach of animals has been used to designate something like
spasmolytic polypeptide-expressing metaplasia (SPEM).
Wang et al. have reported that an aberrant metaplastic lineage
was found in fundic mucosa of mice infected with
Helicobacter felis, and this metaplastic lineage expressed
TFF2, reflecting regenerative changes in gastric mucosa
[8–10]. Several reports have indicated that SPEM is a precan-
cerous lesion of gastric carcinoma [11–14], whereas Graham
and Zou suggested that the direct experimental evidence of
SPEM to gastric cancer transition was minimal, and SPEM
should not be used for studies in humans [15]. In many papers,
SPEM is often considered synonymous with pseudopyloric
metaplasia [16–20]. However, in Helicobacter pylori
(H. pylori) gastritis, pyloric and pseudopyloric metaplasias
did not always express TFF2 [4].
Autoimmune gastritis (AIG) is a chronic, progressive in-
flammatory disease which is characterized with marked de-
struction of parietal cells in gastric mucosa by autoimmune
mechanisms resulting in decreased gastric acid secretion
followed by hypergastrinemia via negative feedback reaction
[21–23]. As AIG progresses, severe atrophy of fundic glands
is also accompanied with various kinds of metaplasia, such as
intestinal metaplasia, pyloric/pseudopyloric metaplasia, and
pancreatic acinar cell metaplasia [24–30]. Therefore, AIG is
one of the models to examine TFF2 expression in pyloric/
pseudopyloric metaplasia.
In this study, we examined the numbers of TFF2 express-
ing glands in pyloric/pseudopyloric metaplasia glands and
confirmed whether SPEM can be used for pseudopyloric
metaplasia in human materials.
Materials and methods
Subjects
We retrospectively reviewed the biopsy specimens of consec-
utive 22 patients (7 male and 15 female) who underwent
esophagogastroduodenoscopy and who were clinically and
histopathologically diagnosed as AIG in Japan Community
Healthcare Organization (JCHO) Shiga Hospital, Japan,
between May 2012 and January 2020. Diagnosing criteria
for AIG consisted of positivity of either serum anti-parietal
cell or anti-intrinsic factor antibodies, accompanied with at
least one of the following four items: increased serum
gastrin, severe endoscopic gastric mucosal atrophy, strong-
ly positive (3+) serum PG test, and decreased serum vita-
min B12, and also being satisfied with histopathological
criteria as described later. Serum gastrin, PG, and vitamin
B12 were measured with Gastrin RIA Kit II (Fujirebio),
ARCHITECT Pepsinogen I and II (Abbott Japan, Tokyo,
Japan), and Beckman Coulter ACCESS B12 (Beckman
Coulter), respectively.
In order to confirm the infection status ofH. pylori, history
about the pastH. pylori tests and therapies was collected from
the medical records. H. pylori tests included serum H. pylori
antibody test (HpAb) (E-plate Eiken H. pylori antibody II,
Eiken Kagaku, Tochigi, Japan), H. pylori stool antigen
test (HpSA) (Meridian HpSA ELISA II, Fujirebio), urea
breath test (UBT) (Ubit Tablets 100 mg, Otsuka
Pharmaceutical , Tokyo, Japan; POCone, Otsuka
Electronics, Osaka, Japan), histopathology (H&E staining
and Giemsa staining), and culture for H. pylori. Serum
anti-H. pylori was tentatively judged negative when the
ELISA value was below 10.0 U/mL according to the man-
ufacturer’s instruction. HpSA was tentatively judged pos-
itive with the value 0.120 or more and negative with the
values less than 0.100. UBT was tentatively judged neg-
ative with the delta-13CO2 less than 2.0‰ and positive
with the value 5.0‰ or more. Patients with clear evidence
of current H. pylori infection with pathology or culture
were determined “currently infected.” Those showing no
evidence of infection by all the tests performed were di-
agnosed “not infected.” Those who had past eradication
therapy were included in “past infected.” Other patients
were diagnosed either of the above three status from the
combination of multiple tests and their chronological
changes. Therefore, patients with current H. pylori infec-
tion were not included in this study.
Histopathological examination of AIG
Biopsy specimens were collected from greater curvature of the
middle corpus and antrum endoscopically by three-points bi-
opsy or five-points biopsy. In three-points biopsy, we collect-
ed biopsy specimens from greater curvature of the middle
corpus and antrum and lesser curvature of the angulus. In
five-points biopsy, we collected biopsy specimens from great-
er curvature of the middle corpus and antrum, and lesser cur-
vature of the middle corpus, angulus, and antrum according to
the Updated Sydney System (USS). Among them, we evalu-
ated specimens taken from greater curvature of the middle
corpus and antrum in this study. USS proposes that “B2”
and “A2” are the best biopsy sites to evaluate the histopatho-
logical status of fundic and antral mucosa, respectively [31].
Biopsy specimens of all patients were taken once per patient,
and each specimen was put into separate vials. Biopsy speci-
mens were immediately fixed in 10% neutral buffered
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formalin for 24 h and embedded in paraffin. Fixed samples
were serially sliced into 3-μm-thick sections and stained with
H&E. According to the previous reports, the histopathology
was classified into three stages with H&E-stained sections:
early, florid, and end stages [24–28]. The early stage consisted
of moderate inflammatory cell infiltration in the lamina
propria and decreased parietal cells. The florid stage consisted
of marked atrophy of fundic glands with diffuse
lymphoplasmacytic infiltration. The end stage consisted of
reduced inflammatory cell infiltrates and complete parietal
cell loss [32]. AIG was comprehensively diagnosed by two
pathologists with more than 20 years of diagnostic experience.
Inflammation, activity, atrophy, and intestinal metaplasia
of greater curvature of the middle corpus were evaluated with
the USS (0, none; 1, mild; 2, moderate; 3, marked) [31]. In
addition, the lymphoid follicles and lymphocyte aggregation
(LF/LA) were also examined and scored (0, none; 1, small
lymphocyte aggregation; 2, 1 or 2 lymphoid follicles were
observed; and 3, more than 3 lymphoid follicles were
observed).
Evaluation of AIG with immunohistochemical staining
In AIG, gastrin cell hyperplasia is often recognized in
the antrum [3]. On the other hand, linear and nodular
types of enterochromaffin cell-like (ECL) cell hyperpla-
sia are seen in the corpus in florid or end stages [26,
33]. Linear type is recognized as clusters of hyperplastic
ECL cells lining in the glands and nodular type as clus-
ters of ECL cells out of the glands in the lamina
propria. In recent years, BCL-10 is reported to be pos-
itive in pancreatic acinar cell metaplasia [34, 35]. We
counted the numbers of H+/K+-ATPase-positive cells,
ECL cells, and gastrin cells per each section. Then,
we measured the size of each section and we calculated
the cell density per each section. Thus, the densities of
parietal cells, ECL cells, and gastrin cells and the pres-
ence of pancreatic acinar cell metaplasia were examined
in each immunohistochemically stained section.
For immunohistochemical examination, the following an-
tibodies were used as primary antibodies: anti-H+/K+-ATPase
α (1:10000; Medical & Biological Laboratories, Nagoya,
Japan, cat. no. 024) for parietal cells, anti-chromogranin A
(diluted; Roche, Basel, Switzerland, cat.760-2519) for ECL
cells, anti-BCL-10 (1:100; Santa Cruz Biotechnology, Santa
Cruz, CA, USA, cat. SC-5273) and anti-α-amylase (1:1000;
Cell Signaling Technology, Danvers, MA, USA, cat. no.
3796) for pancreatic acinar cell metaplasia, and anti-gastrin
(diluted; Dako, Glostrup, Denmark, cat. IR519) for gastrin
cells. An automated immunostaining device was used for im-
munostaining (Ventana; Discovery XT, Roche Diagnostics
K.K., Tokyo, Japan). Immunohistochemical examination
was performed at Shiga University of Medical Science.
Image analysis software (WinROOF2018; Mitani
Corporation, Fukui, Japan) was used to measure the size of
the section.
Evaluation of pyloric gland-like metaplasias
In the corpus mucosa, we classified pyloric gland-like
glands into pyloric and pseudopyloric metaplasias.
Briefly, anti-MUC6 (diluted; Cell Signaling Technology,
cat.760-4390) and anti-PGI (1:40; BIO RAD, Hercules,
CA, USA, cat.7240-1009) antibodies were used for the
immunohistopathological differentiation of these metapla-
sias. Pyloric and pseudopyloric metaplasias were identified
as in the following: MUC6-positive/PGI-negative for pylo-
ric metaplasia and MUC6-positive/PGI-positive for
pseudopyloric metaplasia. We also examined TFF2 expres-
sion in pyloric and pseudopyloric glands by anti-TFF2 an-
tibody (1:600; Proteintech, Rosemont, IL, USA, cat.D031-
3) with immunohistochemical staining. We counted the
numbers of pyloric and pseudopyloric metaplasia glands
in all the sections. Then, the numbers of TFF2 expressing
glands in pyloric and pseudopyloric metaplasias were
counted in all the sections.
Statistical analysis
The Mann-Whitney test was used to evaluate the densities of
H+/K+-ATPase-positive parietal cells, ECL cells, and gastrin
cells. The chi-square test was used to evaluate the TFF2-
positive gland ratio between pyloric and pseudopyloric
metaplasias. SPSS (Stats Guild Inc. Chiba, Japan) was used
in each analysis, and a value of P<0.05 was considered
significant.
Results
Histopathological evaluation of AIG
The mean USS scores in greater curvature of the middle cor-
pus of 22 AIG subjects were as follows: atrophy 3.0 ± 0.0,
inflammation 2.1 ± 0.2, activity 0.0 ± 0.0, intestinal metaplasia
1.0 ± 0.8, and LF/LA 1.3 ± 0.7. Histopathological staging
revealed that there were no cases in the early stage, 4 cases
in the florid stage, and 18 cases in the end stage (Fig. 1). In
greater curvature of the middle corpus, H+/K+-ATPase-posi-
tive parietal cells were found in 6 of 22 cases (4 in florid and 2
in end stages), and the mean density of the cell was signifi-
cantly greater in florid stage than that in end stage (P<0.01,
Mann-Whitney test; Table 1). Chromogranin A-positive linear
and nodular ECL cell hyperplasia was observed in all cases
(Fig. 2). The mean cell density was not significantly different
between florid and end stages in both linear and nodular types
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(P=0.65 and 0.71 respectively, Mann-Whitney test; Table 1).
BCL-10-positive pancreatic acinar cell metaplasia was not
observed in florid stage, but observed in 2 cases in end stage;
1 of the cases was also stained with α-amylase but the other
was not (Fig. 2). Gastrin-positive cells were found in all cases
in greater curvature of the antrum, but the mean density of the
cell was not significantly different between florid and end
stages (P=0.69, Mann-Whitney test; Table 1). Gastrin-
Table 1 Comparison ofmean cell
densities between stages of AIG Immunohistochemical cell type Mean cell densities (cells/mm
2) p value*
Stage of AIG
Florid stage (N = 4) End stage (N = 18)
H+/K+-ATPase-positive cells in the corpus 11.18 0.33 <0.01
Linear type ECL cells in the corpus 27.63 21.63 0.65
Nodular type ECL cells in the corpus 5.45 6.40 0.71
Gastrin cells in the antrum 165.98 160.83 0.69
Gastrin cells in the corpus 3.08 5.30 0.34
The numbers of H+ /K+ -ATPase-positive cells, ECL cells, and gastrin cells were counted per each section. The
size of each section was measured and the cell density was calculated per each section
AIG autoimmune gastritis, H+ /K+ -ATPase hydrogen potassium ATPase, ECL cells enterochromaffin cell-like
cells
*Comparison between florid and end stages; Mann-Whitney test
Fig. 1 Light microscopic pictures of the typical AIG cases in florid and
end stages (H&E stain, low (a, c) and high (b, d) power magnifications).
In the florid stage, the parietal cells are extensively reduced and persistent
inflammation is observed (a). Parietal cells are under destruction (b:
arrow). In the end stage, parietal cells are completely lost and
inflammatory cell infiltrates are reduced (c). Pyloric-like glands are seen
in the bottom of the mucosa (d). Scale bar: 200μm
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positive cells were also found in greater curvature of the
middle corpus in 14 cases (1 in florid and 13 in end stage),
but the intensity of gastrin staining was weak in the corpus
compared with that in the antrum (Fig. 3). The mean
gastrin-positive cell density in the corpus was not signifi-
cantly different between florid and end stages (P=0.34,
Mann-Whitney test; Table 1). No gastric neoplasm such
as carcinoma or neuroendocrine cell tumor was found in
any of the cases.
TFF2 expression in pyloric and pseudopyloric
metaplasias
TFF2 expression in pyloric and pseudopyloric metaplasias
was examined in greater curvature of the middle corpus.
Pyloric metaplasia was seen in all the cases, but pseudopyloric
metaplasia was found in 15 cases (Table 2). TFF2-positive
pyloric gland-like glands were found in 20 cases (Table 2).
Pseudopyloric metaplasia was found in all the cases in florid
stage, but not all in end stage. On the other hand, TFF2-
positive glands were vice vasa (Table 2).
There were 4 types of MUC6-positive metaplasia
glands in the immunohistochemical stainings with PGI
and TFF2 (Fig 4). Of 1567 pyloric gland–like glands in
all the cases, 1381 (88.1%) glands were negative for PGI
(pyloric metaplasia), and 186 (11.9%) glands were posi-
tive for PGI (pseudopyloric metaplasia). TFF2-positive
and negative glands were found in both pyloric and
pseudopyloric metaplasias. TFF2-positive glands were
recognized in 409 of 1381 (26.9%) PGI-negative glands
and 27 of 186 (14.5%) PGI-positive glands. There was a
significant difference in the TFF2-positive gland ratio
between PGI-negative and positive glands (P<0.01, chi-
square test; Table 3). We also counted the numbers of py-
loric gland–like glands with gastrin cells because gastrin-
positive cells were found in greater curvature not only of
the antrum but of corpus as mentioned above. Gastrin-
positive cells in the corpus were seen in 58 of 1567 meta-
plasia glands. These gastrin-positive cells were only found
in pyloric but not in pseudopyloric metaplasia glands.
However, gastrin-positive cells were found irrespective
whether the gland was TFF2-positive or not (Table 4).
Discussion
In this study, we clearly demonstrated that TFF2-positive
glands (SPEM) were not always the same as PGI-positive
Fig. 2 Light microscopic pictures of the typical AIG cases with H&E (a,
c, e) and immunohistochemical stainings with anti- H+/K+-ATPase (b, h),
anti-Chromogranin A (d), anti-BCL-10 (f) and anti-α-amylase (g).
Parietal cells are significantly reduced in the oxyntic mucosa in a case
of florid stage (a, b). ECL cell hyperplasia is recognized in the corpus
mucosa in linear (black arrowhead) and nodular types (red arrowhead) in
a case of florid stage (c, d). Pancreatic acinar cell metaplasia is found in
the oxyntic mucosa of a case in end stage which showed BCL-10 positive
(f black arrow), α-amylase vague (g red arrow), and H+/K+-ATPase neg-
ative (h). Scale bar 200μm
Virchows Arch
glands (pseudopyloric metaplasia) and were overlapped with
both PGI-positive and negative glands (Table 3). In addition,
TFF2-positive glands were more frequently overlapped with
PGI-negative than positive glands in the AIG patients
(Table 3). In other words, TFF2 expression was more frequent
with pyloric metaplasia than pseudopyloric metaplasia.
Although SPEM has been considered synonymous with
pseudopyloric metaplasia in many papers [16–20], it is con-
firmed that SPEM is not the same as pseudopyloric
metaplasia.
Fig. 3 Light microscopic pictures
for gastrin cells in serial sectioned
slides in the antrum (a, b) and
corpus (c, d) in typical AIG cases:
H&E (a, c) and
immunohistochemical staining
with anti-gastrin (b, d). Gastrin-
positive cells are recognized in
the pyloric glands in the antrum
(b). Gastrin-positive cells are also
seen in the pyloric gland-like
metaplasia glands in the corpus
(d). The intensity of gastrin stain-
ing is weak in the corpus com-
pared with that in the antrum.
Scale bar: 200μm
Table 2 Numbers of cases
containing each pyloric gland-like
metaplasia in AIG
Metaplasia Stage of AIG total
Florid stage (N = 4) End stage (N = 18)
No. of cases Ratio* No. of cases Ratio* No. of cases Ratio*
Pyloric 4 100.0% 18 100.0% 22 100.0%
Pseudopyloric 4 100.0% 11 61.1% 15 68.2%
TFF2 expression 2 50.0% 18 100.0% 20 90.9%
Number of cases 4 18 22
AIG autoimmune gastritis, TFF2 trefoil family factor 2
*Ratio of cases containing each metaplasia in each stage of AIG
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From now, the terms pyloric metaplasia, pseudopyloric
metaplasia, and SPEM should be used properly. Our results
strongly support the opinion that SPEM is just a term pro-
posed from animal studies, and we should not use SPEM
for human materials because TFF2 expression in pyloric
and pseudopyloric metaplasias is limited [15]. Or at least,
when we use the concept of SPEM in humans, SPEM
should not be considered the same as pseudopyloric
metaplasia.
We also showed that gastrin-positive cells were not over-
lapped with PGI-positive glands, and PGI-positive glands
were always gastrin-negative (Table 4). TFF2-positivity was
not related to gastrin-positivity. These findings suggest that
gastrin cells were produced in pyloric metaplasia but not in
pseudopyloric metaplasia. Because TFF2 expression has
nothing to do with gastrin cells, it is also consistent with that
SPEM was independent to pyloric or pseudopyloric
metaplasias.
In our AIG patients, the majority of pyloric gland-like
metaplasia glands were PGI-negative (88.1%, Table 3). In
addition, only 61.1% cases contained pseudopyloric metapla-
sia in end stage in spite that all the cases contained
pseudopyloric metaplasia in the florid stage. It may suggest
that some pseudopyloric metaplasia glands disappeared in the
progression of atrophy and that pseudopyloric metaplasia may
be observed only in the limited term. Or there is a possibility
that pseudopyloric metaplasia glands might have changed into
pyloric metaplasia glands with the progression of atrophy.
These are very similar to the findings in the metaplasias in
H. pylori gastritis.We recently reported that atrophy was more
severe in the cases with pyloric metaplasia than in those with
pseudopyloric metaplasia inH. pylori gastritis [4]. These find-
ings suggest that pseudopyloric metaplasia occurs first in the
process of atrophy and then changed to pyloric metaplasia
according to the progression of atrophy.
On the other hand, TFF2 expression was vice versa
(Table 2). TFF2 expression in AIG has not been studied much
[36], but investigated in H. pylori gastritis [17]. Xia et al.
reported that TFF2 expression was found more frequently in
the cases with severe atrophy. These findings support that
TFF2 expression may tend to occur in the cases with severe
atrophy.
We have discussed AIG and its metaplasia, though, we
should mention that this study has some limitations. First,
the small number of subjects was studied because AIG
was still uncommon in Asians including Japanese [37,
38]. Second, the metaplastic status of gastric mucosa
might be affected by past H. pylori infection as well as
AIG because past infected patients were included in this
study.
However, the following conclusion could be drawn by
quantitatively and closely observing metaplastic glands in
each case; SPEM is not the same as pseudopyloric metaplasia
in human AIG, and the majority of metaplasia in AIG is not
pseudopyloric but pyloric metaplasia.
Table 3 Total numbers of
pyloric/pseudopyloric metaplasia
glands with/without TFF2 ex-
pression in all the 22 cases
Metaplasia TFF2 staining Total Percent/total TFF2-positive ratio*
+ −
Pyloric (PGI−) 409 972 1381 88.1% 29.6%
Pseudopyloric (PGI+) 27 159 186 11.9% 14.5%
Total 436 1131 1567 100.0%
Pseudopyloric metaplasia was idenfitied with PGI staining. The numbers of pyloric and pseudopyloric metaplasia
glands were counted in all the 22 sections. Among them, the numbers of TFF2-positive and -negative glands were
also counted
TFF2 trefoil factor family 2, PGI pepsinogen I
*P<0.01, chi-square test
Table 4 Total numbers of metaplasia glands with/without gastrin stain-
ing cells in all the 22 cases
PGI staining Metaplasia Gastrin staining TFF2 staining
+ −
− Pyloric + 11 47
− 398 925
+ Pseudopyloric + 0 0
− 27 159
The numbers of pyloric and pseudopyloric metaplasia glands with gastrin
cells were counted in all the 22 sections. Among them, the numbers of
TFF2-positive and -negative glands were also counted
PGI pepsinogen I, TFF2 trefoil factor family 2
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